ADAM9 and esophageal squamous cell carcinoma: To further investigate whether the plasminogen activator-based pathway was regulated by the protease activity of ADAM9 in ESCC, we introduced ectopic ADAM9 wild-type (WT) or catalytic mutant E348A 23, which is defective in the protease activity, into ADAM9 KO cells.